S&P 500   4,276.10 (+0.05%)
DOW   33,889.26 (-0.27%)
QQQ   329.41 (+0.28%)
AAPL   174.21 (-0.19%)
MSFT   290.98 (-0.12%)
META   175.02 (+0.10%)
GOOGL   120.15 (+0.50%)
AMZN   142.35 (+0.18%)
TSLA   913.03 (+0.11%)
NVDA   187.40 (+2.21%)
NIO   19.89 (-0.95%)
BABA   90.73 (+1.07%)
AMD   100.46 (+2.23%)
MU   63.08 (+2.37%)
T   18.46 (+0.22%)
CGC   3.78 (-6.90%)
F   16.04 (+0.06%)
GE   79.26 (-0.83%)
DIS   122.46 (-0.28%)
AMC   19.96 (-6.55%)
PYPL   98.85 (-0.57%)
PFE   48.46 (-1.64%)
NFLX   245.07 (+1.63%)
S&P 500   4,276.10 (+0.05%)
DOW   33,889.26 (-0.27%)
QQQ   329.41 (+0.28%)
AAPL   174.21 (-0.19%)
MSFT   290.98 (-0.12%)
META   175.02 (+0.10%)
GOOGL   120.15 (+0.50%)
AMZN   142.35 (+0.18%)
TSLA   913.03 (+0.11%)
NVDA   187.40 (+2.21%)
NIO   19.89 (-0.95%)
BABA   90.73 (+1.07%)
AMD   100.46 (+2.23%)
MU   63.08 (+2.37%)
T   18.46 (+0.22%)
CGC   3.78 (-6.90%)
F   16.04 (+0.06%)
GE   79.26 (-0.83%)
DIS   122.46 (-0.28%)
AMC   19.96 (-6.55%)
PYPL   98.85 (-0.57%)
PFE   48.46 (-1.64%)
NFLX   245.07 (+1.63%)
S&P 500   4,276.10 (+0.05%)
DOW   33,889.26 (-0.27%)
QQQ   329.41 (+0.28%)
AAPL   174.21 (-0.19%)
MSFT   290.98 (-0.12%)
META   175.02 (+0.10%)
GOOGL   120.15 (+0.50%)
AMZN   142.35 (+0.18%)
TSLA   913.03 (+0.11%)
NVDA   187.40 (+2.21%)
NIO   19.89 (-0.95%)
BABA   90.73 (+1.07%)
AMD   100.46 (+2.23%)
MU   63.08 (+2.37%)
T   18.46 (+0.22%)
CGC   3.78 (-6.90%)
F   16.04 (+0.06%)
GE   79.26 (-0.83%)
DIS   122.46 (-0.28%)
AMC   19.96 (-6.55%)
PYPL   98.85 (-0.57%)
PFE   48.46 (-1.64%)
NFLX   245.07 (+1.63%)
S&P 500   4,276.10 (+0.05%)
DOW   33,889.26 (-0.27%)
QQQ   329.41 (+0.28%)
AAPL   174.21 (-0.19%)
MSFT   290.98 (-0.12%)
META   175.02 (+0.10%)
GOOGL   120.15 (+0.50%)
AMZN   142.35 (+0.18%)
TSLA   913.03 (+0.11%)
NVDA   187.40 (+2.21%)
NIO   19.89 (-0.95%)
BABA   90.73 (+1.07%)
AMD   100.46 (+2.23%)
MU   63.08 (+2.37%)
T   18.46 (+0.22%)
CGC   3.78 (-6.90%)
F   16.04 (+0.06%)
GE   79.26 (-0.83%)
DIS   122.46 (-0.28%)
AMC   19.96 (-6.55%)
PYPL   98.85 (-0.57%)
PFE   48.46 (-1.64%)
NFLX   245.07 (+1.63%)
NASDAQ:GTXI

GTX - GTXI Stock Forecast, Price & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
Add
Compare
Today's Range
$1.24
$1.37
50-Day Range
$1.20
$7.20
52-Week Range
$0.74
$25.60
Volume
450,732 shs
Average Volume
390,540 shs
Market Capitalization
$30.30 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
GTXI stock logo

About GTX (NASDAQ:GTXI) Stock

GTx, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of medicines for the treatment of stress urinary incontinence (SUI) and prostate cancer. It develops selective androgen receptor modulators (SARMs) for the treatment of breast cancer, SUI, and Duchenne muscular dystrophy; and selective androgen receptor degraders to treat progressive castration-resistant prostate cancer. The company's SARM product candidate is the enobosarm GTx-024, a Phase II proof-of-concept clinical trial for patients with androgen receptor (AR) positive triple-negative breast cancer; and estrogen receptor positive and AR positive advanced breast cancer, as well as postmenopausal women with SUI. GTx, Inc. was founded in 1997 and is headquartered in Memphis, Tennessee.

Receive GTXI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for GTX and its competitors with MarketBeat's FREE daily newsletter.

GTXI Stock News Headlines

See More Headlines

Receive GTXI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for GTX and its competitors with MarketBeat's FREE daily newsletter.

GTXI Company Calendar

Last Earnings
11/15/2018
Today
8/18/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:GTXI
CUSIP
40052B10
Fax
N/A
Employees
21
Year Founded
N/A

Profitability

Net Income
$-38,420,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$1.09 per share

Miscellaneous

Free Float
N/A
Market Cap
$30.30 million
Optionable
Optionable
Beta
2.22

Key Executives

  • Dr. Robert James Wills B.S. (Age 65)
    M.S., Ph.D., Exec. Chairman
  • Mr. Marc S. Hanover (Age 56)
    Co-Founder, CEO & Director
  • Mr. Henry P. Doggrell (Age 70)
    VP, Chief Legal Officer & Sec.
  • Mr. Jason T. Shackelford (Age 44)
    VP of Fin. & Accounting, Principal Financial & Accounting Officer and Corp. Controller
  • Dr. Diane C. Young (Age 62)
    VP & Chief Medical Officer













GTXI Stock - Frequently Asked Questions

How were GTX's earnings last quarter?

GTx, Inc. (NASDAQ:GTXI) posted its quarterly earnings data on Thursday, November, 15th. The biopharmaceutical company reported ($0.39) earnings per share for the quarter, missing the consensus estimate of ($0.30) by $0.09.

What other stocks do shareholders of GTX own?
What is GTX's stock symbol?

GTX trades on the NASDAQ under the ticker symbol "GTXI."

What is GTX's stock price today?

One share of GTXI stock can currently be purchased for approximately $1.26.

How much money does GTX make?

GTX (NASDAQ:GTXI) has a market capitalization of $30.30 million. The biopharmaceutical company earns $-38,420,000.00 in net income (profit) each year or ($1.65) on an earnings per share basis.

How can I contact GTX?

GTX's mailing address is 17 W Pontotoc Ave. Suite 100, MEMPHIS TN, 38103. The official website for the company is www.gtxinc.com. The biopharmaceutical company can be reached via phone at 901-523-9700 or via email at investor.relations@gtxinc.com.

This page (NASDAQ:GTXI) was last updated on 8/18/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.